Bansal V, Kalita J and Misra UK: Diabetic neuropathy. Postgrad Med J. 82:95–100. 2006.PubMed/NCBI View Article : Google Scholar

Kaur S, Pandhi P and Dutta P: Painful diabetic neuropathy: An update. Ann Neurosci. 18:168–175. 2011.PubMed/NCBI View Article : Google Scholar

Román-Pintos LM, Villegas-Rivera G, Rodríguez-Carrizalez AD, Miranda-Díaz AG and Cardona-Muñoz EG: Diabetic polyneuropathy in type 2 diabetes mellitus: Inflammation, oxidative stress, and mitochondrial function. J Diabetes Res. 2016(3425617)2016.PubMed/NCBI View Article : Google Scholar

Dyck PJ, Kratz KM, Karnes JL, Litchy WJ, Klein R, Pach JM, Wilson DM, O'Brien PC, Melton LJ III and Service FJ: The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: The rochester diabetic neuropathy study. Neurology. 43:817–824. 1993.PubMed/NCBI View Article : Google Scholar

Young MJ, Boulton AJ, MacLeod AF, Williams DR and Sonksen PH: A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia. 36:150–154. 1993.PubMed/NCBI View Article : Google Scholar

Jaiswal M, Lauer A, Martin CL, Bell RA, Divers J, Dabelea D, Pettitt DJ, Saydah S, Pihoker C, Standiford DA, et al: SEARCH for Diabetes in Youth Study Group: Peripheral neuropathy in adolescents and young adults with type 1 and type 2 diabetes from the SEARCH for Diabetes in Youth follow-up cohort: A pilot study. Diabetes Care. 36:3903–3908. 2013.PubMed/NCBI View Article : Google Scholar

Veresiu AI, Bondor CI, Florea B, Vinik EJ, Vinik AI and Gâvan NA: Detection of undisclosed neuropathy and assessment of its impact on quality of life: A survey in 25,000 Romanian patients with diabetes. J Diabetes Complications. 29:644–649. 2015.PubMed/NCBI View Article : Google Scholar

Pop-Busui R, Boulton AJ, Feldman EL, Bril V, Freeman R, Malik RA, Sosenko JM and Ziegler D: Diabetic neuropathy: A position statement by the American diabetes association. Diabetes Care. 40:136–154. 2017.PubMed/NCBI View Article : Google Scholar

Vinik AI: Advances in diabetes for the millennium: New treatments for diabetic neuropathies. MedGenMed. 6 (3 Suppl)(S13)2004.PubMed/NCBI

Rathmann W, Ziegler D, Jahnke M, Haastert B and Gries FA: Mortality in diabetic patients with cardiovascular autonomic neuropathy. Diabet Med. 10:820–824. 1993.PubMed/NCBI View Article : Google Scholar

Bansal D, Gudala K, Muthyala H, Esam HP, Nayakallu R and Bhansali A: Prevalence and risk factors of development of peripheral diabetic neuropathy in type 2 diabetes mellitus in a tertiary care setting. J Diabetes Investig. 5:714–721. 2014.PubMed/NCBI View Article : Google Scholar

Diabetes Control and Complications Trial Research Group. Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, Rand L and Siebert C: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 329:977–986. 1993.PubMed/NCBI View Article : Google Scholar

Klein R, Klein BE and Moss SE: Relation of glycemic control to diabetic microvascular complications in diabetes mellitus. Ann Intern Med. 124:90–96. 1996.PubMed/NCBI View Article : Google Scholar

Tesfaye S, Chaturvedi N, Eaton SE, Ward JD, Manes C, Ionescu-Tirgoviste C, Witte DR and Fuller JH: EURODIAB Prospective Complications Study Group. Vascular risk factors and diabetic neuropathy. N Engl J Med. 352:341–350. 2005.PubMed/NCBI View Article : Google Scholar

Action to Control Cardiovascular Risk in Diabetes Study Group. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, et al: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 358:2545–2559. 2008.PubMed/NCBI View Article : Google Scholar

Callaghan BC, Little AA, Feldman EL and Hughes RA: Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev. 6(CD007543)2012.PubMed/NCBI View Article : Google Scholar

Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, Cuddihy R, Cushman WC, Genuth S, Grimm RH Jr, et al: Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: An analysis of the ACCORD randomized trial. Lancet. 376:419–430. 2010.PubMed/NCBI View Article : Google Scholar

Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH and Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 348:383–393. 2003.PubMed/NCBI View Article : Google Scholar

BARI 2D Study Group. Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, Orchard TJ, Chaitman BR, Genuth SM, et al: A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 360:2503–2515. 2009.PubMed/NCBI View Article : Google Scholar

Ardeleanu V, Toma A, Pafili K, Papanas N, Motofei I, Diaconu CC, Rizzo M and Stoian AP: Current pharmacological treatment of painful diabetic neuropathy: A narrative review. Medicina (Kaunas). 56(25)2020.PubMed/NCBI View Article : Google Scholar

Gregory JA, Jolivalt CG, Goor J, Mizisin AP and Calcutt NA: Hypertension-induced peripheral neuropathy and the combined effects of hypertension and diabetes on nerve structure and function in rats. Acta Neuropathol. 124:561–573. 2012.PubMed/NCBI View Article : Google Scholar

Elliott J, Tesfaye S, Chaturvedi N, Gandhi RA, Stevens LK, Emery C and Fuller JH: EURODIAB Prospective Complications Study Group: Large-fiber dysfunction in diabetic peripheral neuropathy is predicted by cardiovascular risk factors. Diabetes Care. 32:1896–1900. 2009.PubMed/NCBI View Article : Google Scholar

Perez-Matos MC, Morales-Alvarez MC and Mendivil CO: Lipids: A suitable therapeutic target in diabetic neuropathy? J Diabetes Res. 2017(6943851)2017.PubMed/NCBI View Article : Google Scholar

Clair C, Cohen MJ, Eichler F, Selby KJ and Rigotti NA: The effect of cigarette smoking on diabetic peripheral neuropathy: A systematic review and meta-analysis. J Gen Intern Med. 30:1193–1203. 2015.PubMed/NCBI View Article : Google Scholar

Papanas N and Ziegler D: Risk factors and comorbidities in diabetic neuropathy: An update 2015. Rev Diabet Stud. 12:48–62. 2015.PubMed/NCBI View Article : Google Scholar

Tesfaye S, Stevens LK, Stephenson JM, Fuller JH, Plater M, Ionescu-Tirgoviste C, Nuber A, Pozza G and Ward JD: Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: The EURODIAB IDDM complications study. Diabetologia. 39:1377–1384. 1996.PubMed/NCBI View Article : Google Scholar

Mazilu L, Stanculeanu DL, Gheorghe AD, Suceveanu AP, Parepa IR, Stoian Pantea A and Suceveanu AI: Clinical impact of association between diabetes and lung cancer. Rev Chim. 70:1149–1151. 2019.

Suceveanu AI, Suceveanu AP, Gheorghe AD and Mazilu L: Diabetes and cancer-is there a link? In: Diabetes and its complications, Gaber AR (ed). InTech, pp119-137, 2017.

Suceveanu AI, Mazilu L, Nitipir C, Stoian AP, Parepa I, Voinea C and Suceveanu AP: Diabetes mellitus raise the risk for interval colorectal cancer and advanced adenomas. Rev Chim. 70:1808–1811. 2019.

Mazilu L, Stanculeanu DL, Gheorghe AD, Voinea F, Suceveanu AP, Pituru S, Diaconu CC, Parepa IR, Pantea Stoian A, Pop CS and Suceveanu AI: Incidence of chemotherapy induced peripheral neuropathy in cancer patients in clinical practice. Farmacia. 66:904–908. 2018.

Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, Malik RA, Maser RE, Sosenko JM and Ziegler D: American Diabetes Association. Diabetic neuropathies: A statement by the American Diabetes Association. Diabetes Care. 28:956–962. 2005.PubMed/NCBI View Article : Google Scholar

Gheorghe G, Stoian AP, Gaman M, Socea B, Neagu TP, Stanescu AMA, Bratu OG, Mischianu DLD, Suceveanu AI and Diaconu CC: The benefits and risks of antioxidant treatment in liver diseases. Rev Chim. 70:651–655. 2019.

Stoian AP, Mitrofan G, Colceag F, Suceveanu AI, Hainarosie R, Pituru S, Diaconu CC, Timofte D, Nitipir C, Poiana C and Serafinceanu C: Oxidative stress in diabetes. A model of complex thinking applied in medicine. Rev Chim. 69:2515–2519. 2018.

Bromberg MB: An electrodiagnostic approach to the evaluation of peripheral neuropathies. Phys Med Rehabil Clin N Am. 24:153–168. 2013.PubMed/NCBI View Article : Google Scholar

Verrotti A, Prezioso G, Scattoni R and Chiarelli F: Autonomic neuropathy in diabetes mellitus. Front Endocrinol (Lausanne). 5(205)2014.

Serhiyenko VA and Serhiyenko AA: Cardiac autonomic neuropathy: Risk factors, diagnosis and treatment. World J Diabetes. 9:1–24. 2018.PubMed/NCBI View Article : Google Scholar

Vinik AI, Erbas T and Casellini CM: Diabetic cardiac autonomic neuropathy, inflammation and cardiovascular disease. J Diabetes Investig. 4:4–18. 2013.PubMed/NCBI View Article : Google Scholar

Vinik AI and Ziegler D: Diabetic cardiovascular autonomic neuropathy. Circulation. 115:387–397. 2007.PubMed/NCBI View Article : Google Scholar

Gaman MA, Dobrica EC, Pascu EG, Cozma MA, Epingeac ME, Gaman AM, Pantea Stoian AM, Bratu OG and Diaconu CC: Cardio metabolic risk factors for atrial fibrillation in type 2 diabetes mellitus: Focus on hypertension, metabolic syndrome and obesity. J Mind Med Sci. 6:157–161. 2019.

Yarandi SS and Srinivasan S: Diabetic gastrointestinal motility disorders and the role of enteric nervous system: Current status and future directions. Neurogastroenterol Motil. 26:611–624. 2014.PubMed/NCBI View Article : Google Scholar

Parkman HP, Yates K, Hasler WL, Nguyen L, Pasricha PJ, Snape WJ, Farrugia G, Koch KL, Calles J, Abell TL, et al: Similarities and differences between diabetic and idiopathic gastroparesis. Clin Gastroenterol Hepatol. 9:1056–1064. 2011.PubMed/NCBI View Article : Google Scholar

Yuan Z, Tang Z, He C and Tang W: Diabetic cystopathy: A review. J Diabetes. 7:442–447. 2015.PubMed/NCBI View Article : Google Scholar

Zaha DC, Kiss R, Hegedűs C, Gesztelyi R, Bombicz M, Muresan M, Pallag A, Zrinyi M, Pall D, Vesa CM and Micle O: Recent advances in investigation, prevention, and management of healthcare-associated infections (HAIs): Resistant multidrug strain colonization and its risk factors in an intensive care unit of a university hospital. Biomed Res Int. 2019(2510875)2019.PubMed/NCBI View Article : Google Scholar

Maiorino MI, Bellastella G and Esposito K: Diabetes and sexual dysfunction: Current perspectives. Diabetes Metab Syndr Obes. 7:95–105. 2014.PubMed/NCBI View Article : Google Scholar

Sáenz de Tejada I, Angulo J, Cellek S, González-Cadavid N, Heaton J, Pickard R and Simonsen U: Pathophysiology of erectile dysfunction. J Sex Med. 2:26–39. 2005.PubMed/NCBI View Article : Google Scholar

Rhoden EL, Telöken C, Sogari PR and Vargas Souto CA: The use of the simplified international index of erectile function (IIEF-5) as a diagnostic tool to study the prevalence of erectile dysfunction. Int J Impot Res. 14:245–250. 2002.PubMed/NCBI View Article : Google Scholar

Enzlin P, Rosen R, Wiegel M, Brown J, Wessells H, Gatcomb P, Rutledge B, Chan KL and Cleary PA: DCCT/EDIC Research Group. Sexual dysfunction in women with type 1 diabetes: Long-term findings from the DCCT/EDIC study cohort. Diabetes Care. 32:780–785. 2009.PubMed/NCBI View Article : Google Scholar

Pop-Busui R, Herman WH, Feldman EL, Low PA, Martin CL, Cleary PA, Waberski BH, Lachin JM and Albers JW: DCCT/EDIC Research Group. DCCT and EDIC studies in type 1 diabetes: Lessons for diabetic neuropathy regarding metabolic memory and natural history. Curr Diab Rep. 10:276–282. 2010.PubMed/NCBI View Article : Google Scholar

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK prospective diabetes study (UKPDS) group. Lancet. 352:837–853. 1998.PubMed/NCBI

Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassaï B, Erpeldinger S, Wright JM, Gueyffier F and Cornu C: Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: Meta-analysis of randomized controlled trials. BMJ. 343(d4169)2011.PubMed/NCBI View Article : Google Scholar

Ramirez MA and Borja NL: Epalrestat: An aldose reductase inhibitor for the treatment of diabetic neuropathy. Pharmacotherapy. 28:646–655. 2008.PubMed/NCBI View Article : Google Scholar

Sharma SR and Sharma N: Epalrestat, an aldose reductase inhibitor, in diabetic neuropathy: An Indian perspective. Ann Indian Acad Neurol. 11:231–235. 2008.PubMed/NCBI View Article : Google Scholar

Chalk C, Benstead TJ and Moore F: Aldose reductase inhibitors for the treatment of diabetic polyneuropathy. Cochrane Database Syst Rev: CD004572, 2007.

Hu X, Li S, Yang G, Liu H, Boden G and Li L: Efficacy and safety of aldose reductase inhibitor for the treatment of diabetic cardiovascular autonomic neuropathy: Systematic review and meta-analysis. PLoS One. 9(e87096)2014.PubMed/NCBI View Article : Google Scholar

Vallianou N, Evangelopoulos A and Koutalas P: Alpha-lipoic acid and diabetic neuropathy. Rev Diabet Stud. 6:230–236. 2009.PubMed/NCBI View Article : Google Scholar

Nickander KK, McPhee BR, Low PA and Tritschler H: Alpha-lipoic acid: Antioxidant potency against lipid peroxidation of neural tissues in vitro and implications for diabetic neuropathy. Free Radic Biol Med. 21:631–639. 1996.PubMed/NCBI View Article : Google Scholar

Nagamatsu M, Nickander KK, Schmelzer JD, Raya A, Wittrock DA, Tritschler H and Low PA: Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care. 18:1160–1167. 1995.PubMed/NCBI View Article : Google Scholar

Ziegler D, Hanefeld M, Ruhnau KJ, Meissner HP, Lobisch M, Schütte K and Gries FA: Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia. 38:1425–1433. 1995.PubMed/NCBI View Article : Google Scholar

Ruhnau KJ, Meissner HP, Finn JR, Reljanovic M, Lobisch M, Schütte K, Nehrdich D, Tritschler HJ, Mehnert H and Ziegler D: Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy. Diabet Med. 16:1040–1043. 1999.PubMed/NCBI View Article : Google Scholar

Ametov AS, Barinov A, Dyck PJ, Hermann R, Kozlova N, Litchy WJ, Low PA, Nehrdich D, Novosadova M, O'Brien PC, et al: The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: The SYDNEY trial. Diabetes Care. 26:770–776. 2003.PubMed/NCBI View Article : Google Scholar

Ziegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, Low PA, Munzel U, Yakhno N, Raz I, Novosadova M, et al: Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: The SYDNEY 2 trial. Diabetes Care. 29:2365–2370. 2006.PubMed/NCBI View Article : Google Scholar

Mijnhout GS, Kollen BJ, Alkhalaf A, Kleefstra N and Bilo HJ: Alpha lipoic acid for symptomatic peripheral neuropathy in patients with diabetes: A meta-analysis of randomized controlled trials. Int J Endocrinol. 2012(456279)2012.PubMed/NCBI View Article : Google Scholar

Han T, Bai J, Liu W and Hu Y: A systematic review and meta-analysis of α-lipoic acid in the treatment of diabetic peripheral neuropathy. Eur J Endocrinol. 167:465–471. 2012.PubMed/NCBI View Article : Google Scholar

Pácal L, Kuricová K and Kaňková K: Evidence for altered thiamine metabolism in diabetes: Is there a potential to oppose gluco- and lipotoxicity by rational supplementation? World J Diabetes. 5:288–295. 2014.PubMed/NCBI View Article : Google Scholar

Thornalley PJ, Jahan I and Ng R: Suppression of the accumulation of triosephosphates and increased formation of methylglyoxal in human red blood cells during hyperglycaemia by thiamine in vitro. J Biochem. 129:543–549. 2001.PubMed/NCBI View Article : Google Scholar

Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, Lin J, Bierhaus A, Nawroth P, Hannak D, et al: Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med. 9:294–299. 2003.PubMed/NCBI View Article : Google Scholar

Sánchez-Ramírez GM, Caram-Salas NL, Rocha-González HI, Vidal-Cantú GC, Medina-Santillán R, Reyes-García G and Granados-Soto V: Benfotiamine relieves inflammatory and neuropathic pain in rats. Eur J Pharmacol. 530:48–53. 2006.PubMed/NCBI View Article : Google Scholar

Haupt E, Ledermann H and Köpcke W: Benfotiamine in the treatment of diabetic polyneuropathy-a three-week randomized, controlled pilot study (BEDIP study). Int J Clin Pharmacol Ther. 43:71–77. 2005.PubMed/NCBI View Article : Google Scholar

Winkler G, Pál B, Nagybéganyi E, Ory I, Porochnavec M and Kempler P: Effectiveness of different benfotiamine dosage regimens in the treatment of painful diabetic neuropathy. Arzneimittelforschung. 49:220–224. 1999.PubMed/NCBI View Article : Google Scholar

Nikolić A, Kacar A, Lavrnić D, Basta I and Apostolski S: The effect of benfothiamine in the therapy of diabetic polyneuropathy. Srp Arh Celok Lek. 137:594–600. 2009.PubMed/NCBI View Article : Google Scholar

Stracke H, Gaus W, Achenbach U, Federlin K and Bretzel RG: Benfotiamine in diabetic polyneuropathy (BENDIP): Results of a randomised, double blind, placebo-controlled clinical study. Exp Clin Endocrinol Diabetes. 116:600–605. 2008.PubMed/NCBI View Article : Google Scholar

Bril V, England J, Franklin GM, Backonja M, Cohen J, Del Toro D, Feldman E, Iverson DJ, Perkins B, Russell JW, et al: Evidence-based guideline: Treatment of painful diabetic neuropathy: Report of the American academy of neurology, the American association of neuromuscular and electrodiagnostic medicine, and the American academy of physical medicine and rehabilitation. Neurology. 76:1758–1765. 2011.PubMed/NCBI View Article : Google Scholar

Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, Jensen TS and Nurmikko T: European Federation of Neurological Societies. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 17:1113–e88. 2010.PubMed/NCBI View Article : Google Scholar

Goldstein DJ, Lu Y, Detke MJ, Lee TC and Iyengar S: Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain. 116:109–118. 2005.PubMed/NCBI View Article : Google Scholar

Ormseth MJ, Scholz BA and Boomershine CS: Duloxetine in the management of diabetic peripheral neuropathic pain. Patient Prefer Adherence. 5:343–356. 2011.PubMed/NCBI View Article : Google Scholar

Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF and Houlden RL: Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med. 352:1324–1334. 2005.PubMed/NCBI View Article : Google Scholar

Rosenstock J, Tuchman M, LaMoreaux L and Sharma U: Pregabalin for the treatment of painful diabetic peripheral neuropathy: A double-blind, placebo-controlled trial. Pain. 110:628–638. 2004.PubMed/NCBI View Article : Google Scholar

Wiffen P, Collins S, McQuay H, Carroll D, Jadad A and Moore A: Anticonvulsant drugs for acute and chronic pain. Cochrane Database Syst Rev. (CD001133)2000.PubMed/NCBI View Article : Google Scholar

Hossain SM, Hussain SM and Ekram AR: Duloxetine in painful diabetic neuropathy: A systematic review. Clin J Pain. 32:1005–1010. 2016.PubMed/NCBI View Article : Google Scholar

Harati Y, Gooch C, Swenson M, Edelman S, Greene D, Raskin P, Donofrio P, Cornblath D, Sachdeo R, Siu CO and Kamin M: Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology. 50:1842–1846. 1998.PubMed/NCBI View Article : Google Scholar

Freeman R, Raskin P, Hewitt DJ, Vorsanger GJ, Jordan DM, Xiang J and Rosenthal NR: CAPSS-237 Study Group. Randomized study of tramadol/acetaminophen versus placebo in painful diabetic peripheral neuropathy. Curr Med Res Opin. 23:147–161. 2007.PubMed/NCBI View Article : Google Scholar

Ghita MA, Caruntu C, Lixandru D, Pitea A, Batani A and Boda D: The quest for novel biomarkers in early diagnosis of diabetic neuropathy. Curr Proteomics. 14:86–99. 2017.

Caruntu C, Negrei C, Boda D, Constantin C, Caruntu A and Neagu M: Biotechnological advances for diagnosis of peripheral diabetic neuropathy. Rom Biotechnol Lett. 19:9846–9858. 2014.

Alsaloum M, Estacion M, Almomani R, Gerrits MM, Bönhof GJ, Ziegler D, Malik R, Ferdousi M, Lauria G, Merkies IS, et al: A gain-of-function sodium channel β2-subunit mutation in painful diabetic neuropathy. Mol Pain. 15(1744806919849802)2019.PubMed/NCBI View Article : Google Scholar

Mendelson WB: A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry. 66:469–476. 2005.PubMed/NCBI View Article : Google Scholar

Keppel Hesselink JM and Schatman ME: EMA401: An old antagonist of the AT2R for a new indication in neuropathic pain. J Pain Res. 10:439–443. 2017.PubMed/NCBI View Article : Google Scholar

Tesfaye S: PL37: A new hope in the treatment of painful diabetic neuropathy? Pain Manag. 6:129–132. 2016.PubMed/NCBI View Article : Google Scholar

Ghadiri-Anari A, Mozafari Z, Gholami S, Khodaei SA, Aboutorabi-Zarchi M, Sepehri F, Nadjarzade A, Rahmanian M and Namiranian N: Dose vitamin D supplementations improve peripheral diabetic neuropathy? A before-after clinical trial. Diabetes Metab Syndr. 13:890–893. 2019.PubMed/NCBI View Article : Google Scholar

Căruntu C, Negrei C, Ghiţă MA, Căruntu A, Bădărău AI, Buraga I, Boda D, Albu A and Brănişteanu D: Capsaicin, a hot topic in skin pharmacology and physiology. Farmacia. 63:487–491. 2015.

Căruntu C and Boda D: Evaluation through in vivo reflectance confocal microscopy of the cutaneous neurogenic inflammatory reaction induced by capsaicin in human subjects. J Biomed Opt. 17(085003)2012.PubMed/NCBI View Article : Google Scholar